Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 22, 1999

View Archived Issues

Interneuron: FY 1998 results

MorphoSys enters licensing agreement with Chiron for HuCAL

Actinova enters collaboration for development of tooth decay treatment

Results of animal studies indicate ability of GeneSwitch to regulate gene therapy

Chugai presents new COX-2 inhibitor series

Compounds for depression and other CNS disorders reported by Akzo Nobel

Improved treatments for BPH in development at Pfizer

Novel squalene synthase inhibitors claimed by Nippon Kayaku

Several setbacks reported with Lundbeck antipsychotic

Integrin receptor antagonists, prodrugs and transdermal iontophoretic administration

Medeva launches Anthra's valrubicin in first market

Unigene obtains E.U. approval for injectable calcitonin product

Bayer claims camptothecin glycoconjugates for use in cancer

Potent and selective DAT ligand identified by RTI and Emory University

Rochester Medical files PMA for FemSoft

Telmisartan reaches U.S. pharmacy shelves

Terprenin: novel immunosuppressant and antiallergic substance under evaluation at Shionogi

FDA grants priority review to SB's Avandia

Japanese group discovers novel microbial metabolite with antitumor and immunosuppressive effects

Cel-Sci and University of Maryland receive award for TB vaccine development

Genzyme collaborates with Canadian researchers to develop cardiovascular disease therapies

Mitsubishi Chemical and Tokyo Tanabe to merge

Vertex initiates phase II psoriasis trial of VX-497

Snow Brand reports new developments concerning cevimeline

Avant receives patent coverage for complement inhibitors

Celebrex approved in first market outside U.S.

PAP mutants licensed by Hughes Institute; potential anticancer and antiviral therapies

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...